Adam Cuker is a Hematology physician affiliated with University of Pennsylvania. OpenAlex indexes 378 publications with 17,870 citations (h-index 62); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- OsciPulse Device for the Prevention of VTE
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
NIH funding
2 NIH research awards on record, funded 2012–2023 per NIH RePORTER. The latest:
- A rapid microfluidic diagnostic assay for the measurement of Direct Oral Anticoagulants from patient whole blood
Flobio, Llc
FY2023$413,054R44HL149480 - A rapid microfluidic diagnostic assay for the measurement of Direct Oral Anticoagulants from patient whole blood
Flobio, Llc
FY2022$1,222,556R44HL149480 - Improving the diagnosis of heparin-induced thrombocytopenia
University of Pennsylvania
FY2015$23,071K23HL112903
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B
New England Journal of Medicine
2024 - Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
British Journal of Cancer
2023 - A Framework for the Development of Living Practice Guidelines in Health Care
Annals of Internal Medicine
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
Nabila Dahodwala, MD
University of Pennsylvania
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”